
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at combining a chemotherapy drug called eribulin mesylate with gemcitabine and cisplatin chemotherapy. It is for people who have bladder cancer or cancer of the cells lining the urinary tract () that has spread to the nearby tissue (
) or has spread to another part of the body.
Doctors often treat advanced bladder cancer with chemotherapy or radiotherapy. Gemcitabine and cisplatin is one of the combinations of chemotherapy drugs that doctors use.
Eribulin mesylate is a chemotherapy drug that’s not been used for bladder cancer before. The researchers think that combining eribulin mesylate with gemcitabine and cisplatin may be better than gemcitabine and cisplatin alone.
The aim of this trial is to compare the combination of eribulin mesylate, gemcitabine and cisplatin with gemcitabine and cisplatin to find
You may be able to enter this trial if you
You cannot enter this trial if you
This is a phase 2 trial. It is an international trial and will recruit about 80 people from different countries around the world.
It is a randomised trial. People taking part will be put into 1of 2 treatment groups. Neither you nor your doctor can choose which group you are in.
People in group 1 will have eribulin mesylate, gemcitabine and cisplatin.
People in group 2 will have gemcitabine and cisplatin.
You have eribulin mesylate as an injection into a vein. You have it once a week for 2 weeks and then a week without treatment. Each 3 week period is called a cycle of treatment.
You have gemcitabine and cisplatin through a drip into a vein. You have gemcitabine once a week for 2 weeks and then a week without treatment. You have cisplatin on the first day of each 3 week treatment cycle.
You can have up to 6 cycles of treatment.
People in group 1 may be able to continue taking eribulin mesylate after stopping gemcitabine and cisplatin. Your doctor will talk to you about this.
You have a diary to record when you go to the toilet to open your bowels. Because it is important you don’t get constipated while on treatment.
The researchers will also ask your permission to take a small piece of the tumour tissue removed when you had your biopsy or surgery, and some extra blood samples. They will use these to find out more about how the treatment works. You don’t have to agree to this if you don’t want. You can still take part in the main trial.
You see the doctor and have some tests before starting treatment. These tests include
The doctor will give you a diary to record when you open your bowels.
During treatment you see the doctor every week for a physical examination and blood tests. You have a scan every 6 weeks.
After finishing treatment you have a scan every 2 months until your cancer starts to grow again.
The most common side effects of the drugs used in this trial include
We have more information on eribulin mesylate, gemcitabine and cisplatin.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Stephen Nicholson
Eisai
Experimental Cancer Medicine Centre (ECMC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”